Ligand Pharmaceuticals Inc. announced the appointment of Matthew Korenberg as vice president of finance and chief financial officer effective Aug. 6.
Korenberg joins Ligand from NeuroCircuit Therapeutics, a developer of drugs to treat genetic disorders affecting the brain, including Down syndrome. He was the firm's founder and CEO. Prior to NeuroCircuit Therapeutics, Korenberg was with Goldman, Sachs & Co. for 14 years in the firm’s New York, London and San Francisco offices. Most recently, he was a managing director in the health care investment banking team, where he advised and financed companies in the biotechnology and pharmaceutical industries.
Prior to Goldman Sachs, Korenberg was a health care investment banker at Dillon, Read & Co. Inc. During his time in banking, Korenberg advised on more than 50 deals representing more than $30 billion of M&A and licensing transactions and raising more than $10 billion in capital.
Ligand is a pharmaceutical company focusing on developing programs that lead to licensing deals or acquiring royalty revenue-generating therapeutic assets. These therapies address a broad spectrum of diseases, including multiple myeloma, diabetes, anemia and osteoporosis.